Patients with moderate to severe dry eye disease experienced statistically significant improvement in signs and symptoms after 2 weeks of dosing with PL9643 and at the 12-week visit, Palatin Technologies announced in a press release.
However, the primary endpoints were not achieved in the phase 2 study in the overall population of patients with mild, moderate and severe dry eye disease at 12 weeks.
The multicenter, randomized, double-masked, vehicle-controlled study enrolled 160 patients who were randomly assigned to receive PL9643 or vehicle. The prespecified endpoints included inferior
Uncategorized